Pharma industry concerns about NZ continue, after Wikileaks reveals 2004 tactics
This article was originally published in Scrip
Executive Summary
The R&D pharmaceutical industry has always had a rather shaky relationship with one of the world's toughest reimbursement bodies, namely the monopoly purchasing power held by New Zealand's pharmaceutical management agency, Pharmac. So it comes as no surprise to read – in a leaked US embassy cable on Wikileaks' website this week – of some of the tactics used by industry to improve access in this rather small market, in value terms.
You may also be interested in...
US FDA head Hamburg declares no one can inspect world on its own
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
FDA's Hamburg declares no one can "inspect world on its own" for poor quality medicines
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Pharma and MSF agree on competition for cheap vaccines, but differ on pricing
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.